Literature DB >> 15168145

Increased serum levels of interleukin-8 in polyarteritis nodosa and Behçet's disease.

Alzírton de Lira Freire1, Manoel Barros Bertolo, Antônio José de Pinho, Adil Muhib Samara, Sandra Regina Muchinechi Fernandes.   

Abstract

The pathogenesis of Behçet's disease (BD) and polyarteritis nodosa (PAN) is not yet well established. Endothelial cells have been shown to express chemokines that are involved in inflammatory processes. Interleukin-8 (IL-8) is a potent chemoattractant and activator of neutrophils. We evaluated serum IL-8 levels in patients with PAN and BD. We measured serum IL-8 levels in 21 patients with BD and 16 with PAN. Sera from 30 age-matched healthy blood donors were used as normal controls. Serum IL-8 levels were measured by an enzyme-linked immunosorbent assay (ELISA). The mean serum IL-8 level of the active BD (1522.31 pg/ml) and that of the active PAN (654.8 pg/ml) was significantly higher than that of the normal controls (40.39 pg/ml, P <0.05). There was no difference in mean serum IL-8 levels between patients with inactive disease and normal controls. We found higher serum levels of IL-8 in those patients with more severe disease. These results suggest that IL-8 may play a role in the pathogenesis of PAN and/or BD. Our study also suggests a possible relation between serum IL-8 levels and the severity of these diseases.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15168145     DOI: 10.1007/s10067-003-0851-x

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  17 in total

Review 1.  Criteria for diagnosis of Behçet's disease. International Study Group for Behçet's Disease.

Authors: 
Journal:  Lancet       Date:  1990-05-05       Impact factor: 79.321

Review 2.  Pathogenesis of vasculitis syndromes.

Authors:  M C Sneller; A S Fauci
Journal:  Med Clin North Am       Date:  1997-01       Impact factor: 5.456

Review 3.  Human endothelium as a source of multifunctional cytokines: molecular regulation and possible role in human disease.

Authors:  G Krishnaswamy; J Kelley; L Yerra; J K Smith; D S Chi
Journal:  J Interferon Cytokine Res       Date:  1999-02       Impact factor: 2.607

4.  Anti-PR-3 antibodies induce endothelial IL-8 release.

Authors:  W Mayet; A Schwarting; A P Barreiros; J Schlaak; M Neurath
Journal:  Eur J Clin Invest       Date:  1999-11       Impact factor: 4.686

5.  Adamantiades-Behçet's disease: serum IL-8 is a more reliable marker for disease activity than C-reactive protein and erythrocyte sedimentation rate.

Authors:  J Katsantonis; Y Adler; C E Orfanos; C C Zouboulis
Journal:  Dermatology       Date:  2000       Impact factor: 5.366

6.  The demonstration of serum interleukin-8 and superoxide dismutase in Adamantiades-Behçet's disease.

Authors:  L M Wang; N Kitteringham; S Mineshita; J Z Wang; Y Nomura; Y Koike; E Miyashita
Journal:  Arch Dermatol Res       Date:  1997-07       Impact factor: 3.017

7.  Enhanced interleukin 8 secretion in circulation of patients with Behçet's disease.

Authors:  A al-Dalaan; S al-Sedairy; S al-Balaa; M al-Janadi; K Elramahi; S Bahabri; S Siddiqui
Journal:  J Rheumatol       Date:  1995-05       Impact factor: 4.666

8.  Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis.

Authors:  R A Luqmani; P A Bacon; R J Moots; B A Janssen; A Pall; P Emery; C Savage; D Adu
Journal:  QJM       Date:  1994-11

Review 9.  Implications for pathogenesis of patterns of injury in small- and medium-sized-vessel vasculitis.

Authors:  J Charles Jennette
Journal:  Cleve Clin J Med       Date:  2002       Impact factor: 2.321

10.  Serum levels of TNF-alpha, sIL-2R, IL-6, and IL-8 are increased and associated with elevated lipid peroxidation in patients with Behçet's disease.

Authors:  Cem Evereklioglu; Hamdi Er; Yusuf Türköz; Mustafa Cekmen
Journal:  Mediators Inflamm       Date:  2002-04       Impact factor: 4.711

View more
  8 in total

1.  Constitutive and LPS-induced expression of MCP-1 and IL-8 by human uveal melanocytes in vitro and relevant signal pathways.

Authors:  Dan-Ning Hu; Mingchao Bi; David Y Zhang; Fei Ye; Steven A McCormick; Chi-Chao Chan
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-08-14       Impact factor: 4.799

Review 2.  Polyarteritis nodosa revisited.

Authors:  Inés Colmegna; José A Maldonado-Cocco
Journal:  Curr Rheumatol Rep       Date:  2005-08       Impact factor: 4.592

Review 3.  Coexistence of vasculitides with familial Mediterranean fever.

Authors:  Kenan Aksu; Gokhan Keser
Journal:  Rheumatol Int       Date:  2011-03-10       Impact factor: 2.631

4.  Behçet's disease: immunological relevance with arthritis of ankylosing spondylitis.

Authors:  Esin Aktas Cetin; Fulya Cosan; Umut Can Kucuksezer; Sema Bilgic; Yonca Cagatay; Ahmet Gul; Gunnur Deniz
Journal:  Rheumatol Int       Date:  2012-05-11       Impact factor: 2.631

5.  Expression of Pro-inflammatory Protein S100A12 (EN-RAGE) in Behçet's Disease and Its Association with Disease Activity: A Pilot Study.

Authors:  Eun Chun Han; Sung Bin Cho; Keun Jae Ahn; Sang Ho Oh; Jihyun Kim; Dong Soo Kim; Kwang Hoon Lee; Dongsik Bang
Journal:  Ann Dermatol       Date:  2011-08-06       Impact factor: 1.444

Review 6.  Hypertrophic pachymeningitis in polyarteritis nodosa: a case-based review.

Authors:  Shun Nomura; Yasuhiro Shimojima; Yasufumi Kondo; Dai Kishida; Yoshiki Sekijima
Journal:  Clin Rheumatol       Date:  2021-11-02       Impact factor: 2.980

7.  Behcet's Disease With Cerebral Artery Infarction Caused by Cerebral Arteritis as an Early Symptom Only With Elevated Interleukin-8.

Authors:  Hao Yin; Yun Song; Meimei Zheng; Ju Han; Jiyou Tang
Journal:  Front Neurol       Date:  2019-10-22       Impact factor: 4.003

8.  Pre-Activated Granulocytes from an Autoimmune Uveitis Model Show Divergent Pathway Activation Profiles upon IL8 Stimulation In Vitro.

Authors:  Anne L C Hoffmann; Stefanie M Hauck; Cornelia A Deeg; Roxane L Degroote
Journal:  Int J Mol Sci       Date:  2022-08-23       Impact factor: 6.208

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.